MCL Research Must Refocus on Sequencing, Goy Says – Targeted Oncology
Targeted Oncology |
MCL Research Must Refocus on Sequencing, Goy Says
Targeted Oncology For example, ZUMA-2, a phase II, multicenter, open-label study is currently evaluating the efficacy of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) in subjects with relapsed or refractory MCL (NCT02601313). |
